Correspondence on “Efficacy,Safety,and Early Relapse after Cessation of Upadacitinib Versus Dupilumab in Adolescents With Moderate-to-Severe Atopic Dermatitis: A Real-World Study in China”
Restricted accessLetterFirst published online November, 2025
Correspondence on “Efficacy,Safety,and Early Relapse after Cessation of Upadacitinib Versus Dupilumab in Adolescents With Moderate-to-Severe Atopic Dermatitis: A Real-World Study in China”
ZhuJ, WuH, YeY, et al.Efficacy, safety, and early relapse after cessation of upadacitinib versus dupilumab in adolescents with moderate-to-severe atopic dermatitis: A real-world study in China. Dermatitis. 2024; 35(6):636–645; doi: 10.1089/derm.2024.0014
2.
SimpsonEL, PappKA, BlauveltA, et al.Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: Analysis of follow-up data from the measure Up 1 and Measure Up 2 randomized clinical trials. JAMA Dermatol. 2022; 158(4):404–413; doi: 10.1001/jamadermatol.2022.0029
3.
SimpsonEL, SinclairR, FormanS, et al.Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020; 396(10246):255–266; doi: 10.1016/S0140-6736(20)30732-7
4.
BlauveltA, Guttman-YasskyE, PallerAS, et al.Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: Results through week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022; 23(3):365–383; doi: 10.1007/s40257-022-00683-2
5.
CorkMJ, ThaçiD, EichenfieldLF, et al.Dupilumab safety and efficacy in a Phase III open-label extension trial in children 6-11 years of age with severe atopic dermatitis. Dermatol Ther (Heidelb). 2023; 13(11):2697–2719; doi: 10.1007/s13555-023-01016-9
